


ICAV
International Consortium
on Anti-Virals



CITAV
Consortium International
sur les Thérapies Antivirales

Jeremy Carver, BA, PhD

CEO/CSO & Co-founder, ICAV

Dr. Carver is an experienced biotechnology entrepreneur, currently he is the President, CEO and CSO of the International Consortium on Anti-Virals (ICAV-CITAV) an organization of over 250 scientists from 28 countries. ICAV is dedicated to discovering and delivering low-cost anti-viral drugs to low and middle income countries. Dr. Carver co-founded ICAV with Dr. Michel Chrétien in June 2004. Founding President, CEO and CSO of GlycoDesign Inc (1994 -2002), a biotech company that in 2001 received the Friesen-Rygiel Award, he is Emeritus Professor at the University of Toronto and an Honorary Conjoint Professor at Trent University. He is also a member of the Advisory Board of the National Research Council of Canada's Institute for Biological Sciences and was a Professor (1968-94) and Associate Dean Basic Science (1989-1992), Faculty of Medicine, University of Toronto. He received a Ph.D. (Biophysics, Harvard University) and an Hons. B.A. (Physics, University of Toronto), a Helen Hay Whitney Postdoctoral Fellowship (Oxford University) and a World Trade Visiting Scientist Award (IBM Watson Labs).